


### **Superior Decision**

SMART Detection™ discriminates safely and effectively. Preliminary results from a recent clinical trial show the absolute sensitivity for the detection of ventricular tachycardias (VT) and 93% specificity for the discrimination of supraventricular tachycardias (SVT).

SMART Detection™ is implemented in BIOTRONIK's complete line of dual chamber ICDs.



## intelligent


SMART compares the interval lengths and analyses rate stability, multiplicity and PR association.




#### Rhythm Classification

SMART Detection™ analyses the interaction between atrial and ventricular rates. The classification is achieved by performing a test sequence using averaged PP and RR intervals. When a VT is determined, therapy is delivered. The SVT decision inhibits the therapy and is documented by IEGM recording.








#### Atrial Fibrillation with Irregular Conduction









# adequate


#### Ventricular Tachycardia with Retrograde Conduction








#### Atrial Tachycardia with Wenckebach Behaviour



### safe



#### Clinical Study

An international clinical multicenter study was conducted in accordance with FDA regulations. Two of the primary features investigated were sensitivity and specificity of the SMART Detection™ algorithm. The Phylax AV ICD system was implanted in a total of 128 patients between June 1998 and August 2000. Mean age, gender and history of these patients correspond to that of the general ICD patient population.

889 tachycardia episodes in 64 patients have been documented.

SMART was activated for 774 episodes.

SMART was deactivated for patients who suffered primarily from VF episodes.

## sensitive

Age:	61 ± 11 years		
Sex:	male	112	(87.5%)
	female	16	[12.5%]
LVEF:		31	± 11%
NYHA*:	class I	20	[14.8%]
	class II	75	(55.5%)
	class III	36	[26.7%]
	class IV	4	(3.0%)

<sup>\*</sup> The sum is more than 128 because some patients were classified to be "between two classes".

### 100% VT-Sensitivity 93% SVT-Specificity

#### Results

The results show that the sensitivity of the SMART Detection™ algorithm for appropriately detecting VT was 100%, whereby delivering all appropriate therapy. The specificity of 89.7% was observed when all patient data profiles were considered. Inappropriate therapies can be reduced by optimising the programming (setting of onset delta, deactivation of safety timer). The specificity for optimised programming is 93.3%.

Inappropriate Therapies			
Safety Timer*	17 (2.2%) in 6 patients		
No Onset*	11 (1.4%) in 5 patients		
Wenckebach	4 (1.4%) in 1 patients		
SVT in VF	4 (1.4%) in 1 patients		
paroxysmal SVT with 1:1-conduction 4 (1.4%) in 1 patient			
other	39 (5.9%) in 9 Patienten		

 $<sup>^{</sup>st}$  avoidable with optimised programming

### effective

#### [1] C. Stellbrink, A. M. Sinha, B. Möx, L. Jordaens, B. Merkely, J. Gill, Phylax AV Study Group

First results with the SMART Detection™ algorithm for the discrimination of supraventricular tachycardias with the implantable defibrillator Phylax AV. 66® Annual Congress of the German Society for Cardiology, Heart and Circulation Research, Mannheim, 2000

#### [2] B. Merkely, J. Witte

Clinical results with the Dual-Chamber Cardioverter Defibrillator Phylax AV – Efficacy of the SMART Discrimination Algorithm. Progress in Biomed. Res. 5 (2), 107–112, 2000

#### [3] A. M. Sinha, C. Stellbrink, D. Karla, A. Hahn, P. Hanrath

Discrimination of Ventricular and Supraventricular Tachycardias with a New Detection Algorithm in a Dual Chamber ICD. Herzschrittmacher 20 (3), 208 – 214, 2000

™ SMART Detection is a Registered Trademark.

© by BIOTRONIK GmbH & Co. Specifications subject to modification, revision and improvement. All rights reserved. Visit our website: www.biotronik.com

BIOTRONIK GmbH & Co. Woermannkehre 1 D-12359 Berlin - Germany Tel [+4930] 68905-600 Fax [+4930] 6852804 sales@biotronik.de

